RxDoctor Payments DataLook up a doctor →

Esther Yoon, MD

Family Medicine · Glendale, CANPI 1174725683

Payments from drug & device makers

$5,779,350in general payments, 2019–2025

Across 201 payments — averaging $28,753 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Co., Ltd.$2.2M
  • Novo Nordisk AS$1.9M
  • GSK$920K
  • Acorda Therapeutics, Inc$637K
  • Novartis$104K
  • Eli Lilly$4K
  • plus $4K from 16 others
$10,790in research payments, 2019–2025

Across 2 payments — averaging $5395.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$11K

What the payments were for

  • Travel & lodging$2756%
  • Food & beverage$4,01294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,779,350 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$73,149
Medicare patients
134
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$50,309
JardianceEmpagliflozin17$28,013
ProliaDenosumab14$23,180
EliquisApixaban19$20,452
JanuviaSitagliptin Phosphate12$17,664
VascepaIcosapent Ethyl18$9,125
Tresiba Flextouch U-200Insulin Degludec13$8,233
LinzessLinaclotide12$7,432
Icosapent Ethyl23$2,414
Rosuvastatin Calcium144$2,126
Telmisartan41$1,730
Levothyroxine Sodium109$1,116
SynthroidLevothyroxine Sodium16$1,085
Chlorpromazine Hcl12$971
Metoprolol Succinate72$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,166$50,30943 claims
Boehringer IngelheimJardiance$63$28,01317 claims
AmgenProlia$132$23,18014 claims
PfizerEliquis$82$20,45219 claims
AbbVieLinzess, Synthroid$854$8,51728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →